Frequency Therapeutics
General Information | |
Business: | We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our proprietary approach, called Progenitor Cell Activation, or PCA, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. Further, these progenitor cells, which are closely related to stem cells, are already resident in the targeted location in the body and programmed to develop and differentiate into specific cell types within an organ. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 37 |
Founded: | 2014 |
Contact Information | |
Address | 19 Presidential Way, Woburn, MA 01801, US |
Phone Number | (866) 389-1970 |
Web Address | http://www.frequencytx.com |
View Prospectus: | Frequency Therapeutics |
Financial Information | |
Market Cap | $426.4mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-23.3 mil (last 12 months) |
IPO Profile | |
Symbol | FREQ |
Exchange | NASDAQ |
Shares (millions): | 6.0 |
Price range | $14.00 - $14.00 |
Est. $ Volume | $84.0 mil |
Manager / Joint Managers | J.P. Morgan/ Goldman Sachs/ Cowen and Company |
CO-Managers | Mizuho Securities |
Expected To Trade: | 10/3/2019 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |